Characterising transgenic APP mutation mouse models of amyloid pathology for use in preclinical immunotherapy

0044 English OPEN
Hvoslef-Eide, Martha;
  • Subject: RC0321 | BF | QR180

No disease-modifying compounds are available to halt disease progression in Alzheimer’s \ud disease (AD). Immunotherapy offers promising possibilities for the manipulation of Aβ levels \ud which the amyloid cascade hypothesis proposes as the causative factor in AD. Howe... View more
Share - Bookmark